Skip to content
Menu

UK CF Infection Biorepository

Biorepository

We have launched the UK CF Infection Biorepository. It addresses a key challenge in CF antimicrobial discovery and development: the difficulty researchers face to access all the sample types they need for preclinical testing.

About the UK CF
Infection Biorepository

The CF AMR Syndicate’s vision is to build and strengthen access to high quality clinically relevant samples, data and expertise. This will enable researchers from academia and industry to quickly identify and translate discoveries into new treatments for infections in people with cystic fibrosis. The Biorepository is a coordinated national network of UK labs, each with existing collections and capability:

Coordinated by Medicines Discovery Catapult (MDC), the Biorepository brings together a network of eight centres, each linked to a specialist CF centre that holds clinics for adults and children with CF
AMR Syndicate Biorepository-03
AMR Syndicate Biorepository-06

Resources held by
labs in the network include:

  • Reference strains and strain panels for common pathogens of the CF lung, including Pseudomonas aeruginosa, Burkholderia cepacia complex and nontuberculous mycobacteria (NTM). These strains are of both CF and non-CF origin; they are typically well-characterised and linked with phenotypic data and whole-genome sequence.
  • Clinical isolates (bacterial and fungal strains isolated from the lungs of people with CF) from patients attending paediatric and adult CF centres across the UK. The isolates include Pseudomonas aeruginosa, Burkholderia cepacia complex, nontuberculous mycobacteria, Stenotrophomonas maltophilia, Achromobacter species, Staphylococcus aureus, Streptococcus spp, Haemophilus Influenzae, Aspergillus species, Exophiala, Rasomsonia. Many of the clinical isolates are genome sequenced with clinical metadata associated. Isolates are available from both longitudinal studies and as multiple isolates from individual patients.
  • Sputum (frozen, whole) with associated clinical metadata.
  • Signposting to centres to support the prospective collection of sputum.
  • Antimicrobial susceptibility testing, including combination testing in different formats and models.

UK CF Infection Biorepository is governed by a management
team and receives ongoing strategic advice from an independent
advisory committee.

Accessing Samples and Capability from the UK CF Infection Biorepository

The UK CF Infection Biorepository supplies samples and engages in collaborative projects with academic and industry researchers in the UK and abroad.

Please complete the enquiry form to submit a request. If we think we can fulfil your sample request, we will set up a call to discuss your needs in more detail. We will then link you up with one or more UK centres that can fulfil your request.

Any submitted access requests are managed centrally by MDC, which coordinates the UK network of participating laboratories. Requests for samples, data and capability are reviewed, approved and fulfilled by the relevant laboratory in the network with terms dependent upon the nature of the request.

cf-trust-logo-new
antabio-logo-new
cff-logo

The Biorepository is generously supported
by funding from Cystic Fibrosis Trust, Antabio and The Cystic Fibrosis Foundation.


Contact the CF AMR Syndicate

If you have a question that you can’t find the answer to or would like to get involved with the Syndicate

If you have a question that you can’t find the answer to